CFB
RNAM

Cullen/Frost Bankers’s Avidity Biosciences RNAM Stock Holding History

Cullen/Frost Bankers’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$2.18K – 1516
2025
Q3 		$2.18K Buy
+50
New +$2.02K ﹤0.01% 1220

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cullen/Frost Bankers's RNAM Position: Q4 2025 in Review

Cullen/Frost Bankers sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 50 shares — an estimated $2.18K sold.

Cullen/Frost Bankers first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $2.18K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Cullen/Frost Bankers reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Cullen/Frost Bankers sold 50 Avidity Biosciences shares in Q4 2025, an estimated $2.18K.
  • Cullen/Frost Bankers first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
  • Cullen/Frost Bankers's Avidity Biosciences position peaked at $2.18K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Cullen/Frost Bankers's 13F filing for Q4 2025, filed 6 Feb 2026.